Stay updated with breaking news from Eric Benevich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
On February 13, 2024, Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences Inc (NASDAQ:NBIX), executed a sale of 1,098 shares of the company.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2023 Earnings Call Transcript February 7, 2024 Neurocrine Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to Neurocrine Biosciences’ year-end and fourth quarter results call. At this time, all […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective hoisted by UBS Group from $174.00 to $193.00 in a report issued on Tuesday morning, Benzinga reports. UBS Group currently has a buy rating on the stock. Several other equities research analysts have also recently issued reports on NBIX. Needham & Company LLC reaffirmed a […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2023 Earnings Call Transcript October 31, 2023 Operator: Good day, everyone. And welcome to the Neurocrine Biosciences Reports third quarter results. At this time, all participants are in a listen-only mode. Later you will have the opportunity to ask questions during the question-and-answer session. [Operator Instructions] Please note this call […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2023 Earnings Call Transcript August 1, 2023 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS is $-0.18 EPS, expectations were $0.77. Operator: Good day, everyone, and welcome to today’s Neurocrine Biosciences Reports Second Quarter Results. [Operator Instructions] It is now my pleasure to turn today’s program over to Todd […]